A new study confirms previous research that cannabis use can eliminate chronic pain
Chronic pain is something that affects a large part of the population today, especially older adults. Different studies have said that cannabidiol’s (CBD) ability to relieve the sensation of pain in humans has been limited due to low bioavailability. However, the Lewis Katz School of Medicine at Temple University has taken on the task of creating a new study, suggesting that this obstacle can be overcome with a new CBD analog known as KLS-13019.
As evidence of the vast number of people suffering from chronic pain, studies showed that, in 2017 alone, around 18 million Americans abused prescription painkillers during the previous year, and this number has continued to rise as time goes on. Addictions of these opioids are problems that society has to deal with, and that’s why several types of research have explored different alternatives. This is where CBD, a non-psychoactive cannabis compound, comes into play.
Sara Jane Ward, Ph.D., assistant professor of pharmacology at the Katz School of Medicine, explains, “In a mouse model of chemotherapy-induced peripheral neuropathy (CIPN), we were able to demonstrate for the first time that KLS-13019 works as well, if not better, than CBD in preventing the development of neuropathy and reversing pain. sensitivity after pain has been established.”
The scientists, after seeing that the results were promising, began trying to understand the pain-relieving capabilities of KLS-13019, relative to CBD, in animals with CIPN, which is a side effect that comes from cancer treatments. In humans, it can manifest in a variety of ways, including tingling or burning sensations and numbness, weakness, or discomfort in the extremities. As a result, the researchers found that pain sensitivity was greatly reduced in animals with CIPN that were treated with KLS-13019 or CBD, indicating that the effects have a positive impact on this type of discomfort.